Skip to main content
Premium Trial:

Request an Annual Quote

Richard Kniss, VW Brinkerhoff III, Andrew Carr, John Padfield, Craig Taylor, Jennifer Collins, Tim Keith, , Randall Little, Paul Van Eerdewegh, Jonathan Segal, Majid Belouchi, John Raelson


Richard Kniss will be appointed non-executive chairman of Arcturus, the company said this week. He has been a board member since 2002. Kniss was senior vice president and general manager of the life science and chemical group of Agilent Technologies prior to his retirement in 2001.

VW Brinkerhoff III has joined Gene Logic as senior vice president and general manager for its preclinical contract research business, the Gaithersburg, Md.-based company said this week. Prior to joining Gene Logic, he was group vice president for operations at Wilson Greatbatch Technologies. Earlier, he held senior management positions with Life Technologies, now Invitrogen.

Andrew Carr has become executive chairman of the board of Akubio, the Cambridge, UK-based company said this week. He replaces John Padfield, who stepped down as non-executive chairman to focus on other business commitments. Carr used to be CEO of Amersham Biosciences and director of Amersham.

Following the merger of Lynx Therapeutics and Solexa this week, John West, Solexa's chief executive, has become CEO of the combined company, also called Solexa. The board of the merged company will include members from both companies' boards. Craig Taylor, previously Lynx Therapeutics' chairman, will chair the new board.

Jennifer Collins has been promoted to principal accounting officer and principal financial officer of Orchid Biosciences, the company said in an SEC filing last week. She joined the company as corporate controller in March 2004. Collins holds a BS degree in accounting from Lehigh University.

Genizon BioSciences, formerly Galileo Genomics, has hired four former Genome Therapeutics (now Oscient Pharmaceuticals) scientists and promoted two of its own staff, the Montreal-based company said this week.

Tim Keith has joined the company as vice president and chief scientific officer. He is the former head of the human genetics group at Genome Therapeutics. In addition, Randall Little has become executive director for computational biology, Paul Van Eerdewegh senior director for statistical genetics, and Jonathan Segal senior scientific software engineer for bioinformatics and statistical genetics.

Also, Majid Belouchi has been promoted to vice president and chief technology officer, and John Raelson to chief geneticist. Both are company founders.


Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.